García María Concepción, Cinquina Valentina, Palomo-Garo Cristina, Rábano Alberto, Fernández-Ruiz Javier
Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Investigación en Neuroquímica, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Spain.
Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Investigación en Neuroquímica, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Department of Theoretical and Applied Sciences, University of Insubria, Italy.
Neurosci Lett. 2015 Feb 5;587:1-4. doi: 10.1016/j.neulet.2014.12.003. Epub 2014 Dec 3.
It is well-demonstrated that cannabinoid CB2 receptors located in glial cells are up-regulated in neurodegenerative disorders serving as a target to control glial influences to neurons. Recent evidence indicates that CB2 receptors may be also located in certain neuronal subpopulations and serve as a marker of neuronal losses. We investigated this possibility in the post-mortem substantia nigra of Parkinson's disease (PD) patients and controls. Immunostaining for the CB2 receptor was found in tyrosine hydroxylase-positive neurons in the substantia nigra, a fact confirmed with double-staining analyses. The signal was found in controls but also in PD patients, in which CB2 receptor labelling was significantly lower, in parallel to the losses of these neurons experienced in the disease. These data show for the first time that CB2 receptors are located in tyrosine hydroxylase-containing neurons in the substantia nigra at levels significantly lower in PD patients compared to controls.
已有充分证据表明,位于胶质细胞中的大麻素CB2受体在神经退行性疾病中上调,可作为控制胶质细胞对神经元影响的靶点。最近的证据表明,CB2受体也可能位于某些神经元亚群中,并作为神经元损失的标志物。我们在帕金森病(PD)患者和对照组的尸检黑质中研究了这种可能性。在黑质中酪氨酸羟化酶阳性神经元中发现了CB2受体的免疫染色,这一事实通过双重染色分析得到证实。在对照组和PD患者中均发现了该信号,但在PD患者中CB2受体标记明显较低,这与疾病中这些神经元的损失情况一致。这些数据首次表明,与对照组相比,PD患者黑质中含酪氨酸羟化酶的神经元中CB2受体的水平明显较低。